個(gè)人簡(jiǎn)介：

張瑞坤現任突破藥業(yè)聯(lián)合創(chuàng )始人、首席商務(wù)官，負責公司融資、商務(wù)合作及對外交流。此前曾任漢康資本投資合伙人，負責早期孵化和投后管理；意大利 NMS Group 大中華區首席商務(wù)官，負責集團公司業(yè)務(wù)合作、融資和商務(wù)拓展。張瑞坤曾是先聲藥業(yè)百家匯創(chuàng )始管理團隊成員，擔任百家匯執行總監，先聲藥業(yè) JITRI 轉化醫學(xué)和創(chuàng )新藥物技術(shù)研究所副所長(cháng)，負責商務(wù)合作、孵化管理及投資國內外創(chuàng )新研發(fā)團隊。在此之前，先后擔任美國 CRO，XBL-CHINA 業(yè)務(wù)發(fā)展總監、加拿大最大藥企 Apotex Inc.資深科學(xué)家和項目經(jīng)理等職位。在北美、歐洲和中國生命科學(xué)領(lǐng)域積累了豐富的專(zhuān)業(yè)知識、商務(wù)拓展、管理及投資經(jīng)驗。張瑞坤擁有中國藥科大學(xué)生化制藥學(xué)士學(xué)位，馬斯特里赫特商學(xué)院 MBA 學(xué)位。

公司簡(jiǎn)介：

Tupos Therapeutics is discovering breakthrough therapies to address large, persistent unmet?medical needs. We have a vigorous pipeline comprised of high value targets with disruptive?approaches in immunology and oncology. Tupos’ team consists of experienced drug hunters?and industrial leaders with a proven track record. Our battle-tested drug discovery platform?grounded in best practices of small molecule drug discovery over the last two decades,?strengthened by emerging technologies. Our global perspective and cross-border execution,?along with strategic partnerships with global pharmaceutical companies, allow us to transform?cutting-edge innovations into clinically validated treatments for the global market.